Literature DB >> 33902757

Drug target ranking for glioblastoma multiforme.

Radhika Saraf1,2, Shaghayegh Agah3, Aniruddha Datta4, Xiaoqian Jiang3.   

Abstract

BACKGROUND: Glioblastoma Multiforme, an aggressive primary brain tumor, has a poor prognosis and no effective standard of care treatments. Most patients undergoing radiotherapy, along with Temozolomide chemotherapy, develop resistance to the drug, and recurrence of the tumor is a common issue after the treatment. We propose to model the pathways active in Glioblastoma using Boolean network techniques. The network captures the genetic interactions and possible mutations that are involved in the development of the brain tumor. The model is used to predict the theoretical efficacies of drugs for the treatment of cancer.
RESULTS: We use the Boolean network to rank the critical intervention points in the pathway to predict an effective therapeutic strategy for Glioblastoma. Drug repurposing helps to identify non-cancer drugs that could be effective in cancer treatment. We predict the effectiveness of drug combinations of anti-cancer and non-cancer drugs for Glioblastoma.
CONCLUSIONS: Given the genetic profile of a GBM tumor, the Boolean model can predict the most effective targets for treatment. We also identified two-drug combinations that could be more effective in killing GBM cells than conventional chemotherapeutic agents. The non-cancer drug Aspirin could potentially increase the cytotoxicity of TMZ in GBM patients.

Entities:  

Keywords:  Boolean network modeling; Cancer; Drug repurposing; Drug resistance; Drug target ranking; Glioblastoma

Year:  2021        PMID: 33902757     DOI: 10.1186/s42490-021-00052-w

Source DB:  PubMed          Journal:  BMC Biomed Eng        ISSN: 2524-4426


  1 in total

1.  Pan-cancer analysis of LncRNA XIST and its potential mechanisms in human cancers.

Authors:  Wei Han; Chun-Tao Shi; Jun Ma; Hua Chen; Qi-Xiang Shao; Xiao-Jiao Gao; Ying Zhou; Jing-Feng Gu; Hao-Nan Wang
Journal:  Heliyon       Date:  2022-09-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.